In Wake of Express Scripts Suit, FTC Takes On 3 Largest PBMs

AJMC October 13, 2024
Skylar Jeremias

Key Takeaways

• The FTC accuses major PBMs of inflating insulin prices, impacting patient costs and access to affordable medications.
• PBMs prioritize high-rebate drugs, contributing to high insulin prices and limiting access to cost-effective alternatives.
• Calls for PBM reform focus on transparency and addressing monopolistic practices to improve drug affordability.
• The FTC’s action underscores the need for urgent reforms to address PBMs’ anti-competitive behaviors and improve patient access to affordable medications.

Days after Express Scripts sued the Federal Trade Commission (FTC) over the publication of a report criticizing pharmacy benefit managers (PBMs), the FTC took legal action of its own, accusing the 3 largest PBMs of forcing patients to pay higher costs on insulin products to increase their profits.^1,2

Today's Sponsors

Today's Sponsor